P. Declerck

发表

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study 1

J. Deckers, A. Gils, P. Declerck, 2009, Journal of thrombosis and haemostasis : JTH.

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study

R. Schnabel, D. Tregouet, S. Blankenberg, 2009, Journal of thrombosis and haemostasis : JTH.

University of Birmingham Atherothrombosis and Thromboembolism :

T. Renné, H. Crijns, N. Mackman, 2018 .

The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is critically dependent on TAFI deficiency

A. Gils, H. Lijnen, M. Peeters, 2012, Journal of thrombosis and haemostasis : JTH.

Role of urokinase in the fibrogenic response of the lung to mineral particles.

D. Lison, B. Fubini, C. Lardot, 1998, American journal of respiratory and critical care medicine.

Pathophysiology of fibrinolysis

Jordi Félez, P. Declerck, I. Juhan-vague, 1994, Journal of internal medicine.

Characterization of rat thrombin‐activatable fibrinolysis inhibitor (TAFI) – a comparative study assessing the biological equivalence of rat, murine and human TAFI

A. Gils, A. Macovei, G. Compernolle, 2006, Journal of thrombosis and haemostasis : JTH.

Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children

A. Gils, J. Hazelzet, P. Declerck, 2008, Journal of thrombosis and haemostasis : JTH.

Development of sandwich‐type ELISAs for the quantification of rat and murine thrombin activatable fibrinolysis inhibitor in plasma

A. Gils, P. Declerck, J. Meijers, 2007, Journal of thrombosis and haemostasis : JTH.

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

S. Muyldermans, A. Gils, G. Hassanzadeh-Ghassabeh, 2010, Journal of thrombosis and haemostasis : JTH.

Cloning and paratope analysis of an antibody fragment, a rational approach for the design of a PAI‐1 inhibitor

A. Gils, K. Verbeke, A Gils, 2004, Journal of thrombosis and haemostasis : JTH.

Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1 by a heterodimer diabody

A. Gils, N. Booth, J. Develter, 2008, Journal of thrombosis and haemostasis : JTH.

Evaluation of the profibrinolytic properties of a bispecific antibody‐based inhibitor against human and mouse thrombin‐activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1

A. Gils, T. Wyseure, P. Declerck, 2013, Journal of thrombosis and haemostasis : JTH.

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

S. Muyldermans, A. Gils, G. Hassanzadeh-Ghassabeh, 2011, Journal of thrombosis and haemostasis : JTH.

Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors

A. Gils, P. Declerck, A. Macovei, 2005, Journal of thrombosis and haemostasis : JTH.

Comparative evaluation of stable TAFIa variants: importance of α‐helix 9 and β‐sheet 11 for TAFIa (in)stability

A. Gils, M. de Maeyer, P. Declerck, 2007, Journal of thrombosis and haemostasis : JTH.

Systemic inhibition and liver‐specific over‐expression of PAI‐1 failed to improve survival in all‐inclusive populations or homogenous cohorts of CLP mice

D. Bastelica, M. Alessi, P. Declerck, 2014, Journal of thrombosis and haemostasis : JTH.

Development of anti-matrix metalloproteinase-2 (MMP-2) nanobodies as potential therapeutic and diagnostic tools.

S. Muyldermans, P. Gresele, G. Hassanzadeh-Ghassabeh, 2020, Nanomedicine : nanotechnology, biology, and medicine.

Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity

N. Callewaert, P. Declerck, S. Strelkov, 2016, Journal of thrombosis and haemostasis : JTH.

Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors

C. Blomstrand, A. Gils, C. Jern, 2012, Journal of thrombosis and haemostasis : JTH.

Increased zymogen activity of thrombin‐activatable fibrinolysis inhibitor prolongs clot lysis

A. Gils, G. Compernolle, N. Mishra, 2012, Journal of thrombosis and haemostasis : JTH.

Plasmin and the thrombin–thrombomodulin complex both contribute to thrombin‐activatable fibrinolysis inhibitor activation in whole blood model thrombi

A. Gils, N. Mutch, P. Declerck, 2013, Journal of thrombosis and haemostasis : JTH.

Elucidation of a novel epitope of a substrate‐inducing monoclonal antibody against the serpin PAI‐1

A. Gils, P. Declerck, G. Compernolle, 2003, Journal of thrombosis and haemostasis : JTH.

Reactive site‐dependent phenotypic alterations in plasminogen activator inhibitor‐1 transgenic mice

M. Eren, L. Gleaves, D. Vaughan, 2007, Journal of thrombosis and haemostasis : JTH.

Crystallization and X-Ray Diffraction Data of the Cleaved Form of Plasminogen Activator Inhibitor-1

K. Aertgeerts, H. D. Bondt, P. Declerck, 2022 .

Generation of a stable thrombin‐activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation

P. Declerck, X. Zhou, 2015, Journal of thrombosis and haemostasis : JTH.

Announcing a TAFIa mutant with a 180‐fold increased half‐life and concomitantly a strongly increased antifibrinolytic potential

A. Gils, P. Declerck, M. Peeters, 2007, Journal of thrombosis and haemostasis : JTH.